<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Chikungunya &#8211; Bitfinance</title>
	<atom:link href="https://bitfinance.news/en/etiqueta/chikungunya-en/feed/" rel="self" type="application/rss+xml" />
	<link>https://bitfinance.news</link>
	<description>Fintech &#38; new economy info</description>
	<lastBuildDate>Thu, 09 Apr 2026 10:37:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bitfinance.news/wp-content/uploads/2025/01/favicon-64.png</url>
	<title>Chikungunya &#8211; Bitfinance</title>
	<link>https://bitfinance.news</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Cuba tests drug that relieves painful aftereffects of Chikungunya virus</title>
		<link>https://bitfinance.news/en/cuba-tests-drug-that-relieves-painful-aftereffects-of-chikungunya-virus/</link>
		
		<dc:creator><![CDATA[Marilin Pino]]></dc:creator>
		<pubDate>Thu, 09 Apr 2026 13:00:07 +0000</pubDate>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Other topics]]></category>
		<category><![CDATA[Chikungunya]]></category>
		<category><![CDATA[Clinical Research at the Center for Genetic Engineering and Biotechnology (CIGB)]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[Cuba]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[Julio Baldomero]]></category>
		<category><![CDATA[Jusvinza]]></category>
		<category><![CDATA[Jusvinza drug]]></category>
		<category><![CDATA[medical breakthrough]]></category>
		<category><![CDATA[pain relief]]></category>
		<category><![CDATA[patients]]></category>
		<category><![CDATA[phase 2]]></category>
		<category><![CDATA[recovery]]></category>
		<guid isPermaLink="false">https://bitfinance.news/?p=120625</guid>

					<description><![CDATA[<div style="margin-bottom:20px;"><img width="1100" height="733" src="https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="En Cuba se lleva a cabo la segunda fase de ensayos clínicos del medicamento Jusvinza, un producto de desarrollo local que alivia los síntomas dolorosos, así como la inflamación, en los pacientes que se recuperan del virus chikungunya" decoding="async" fetchpriority="high" srcset="https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash.jpg 1100w, https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash-300x200.jpg 300w, https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash-1024x682.jpg 1024w, https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash-768x512.jpg 768w" sizes="(max-width: 1100px) 100vw, 1100px" /></div><p>The Cuban drug Jusvinza is advancing to the second phase of clinical trials, demonstrating its effectiveness in relieving pain and inflammation in secondary joints in patients recovering from the chikungunya virus. This was reported by Julio Baldomero, director of Clinical Research at the Center for Genetic Engineering and Biotechnology (CIGB). According to the specialist, &#8220;the [&#8230;]</p>
<p>La entrada <a rel="nofollow" href="https://bitfinance.news/en/cuba-tests-drug-that-relieves-painful-aftereffects-of-chikungunya-virus/">Cuba tests drug that relieves painful aftereffects of Chikungunya virus</a> apareció primero en <a rel="nofollow" href="https://bitfinance.news">Bitfinance</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="1100" height="733" src="https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="En Cuba se lleva a cabo la segunda fase de ensayos clínicos del medicamento Jusvinza, un producto de desarrollo local que alivia los síntomas dolorosos, así como la inflamación, en los pacientes que se recuperan del virus chikungunya" decoding="async" srcset="https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash.jpg 1100w, https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash-300x200.jpg 300w, https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash-1024x682.jpg 1024w, https://bitfinance.news/wp-content/uploads/2026/04/louis-reed-pwcKF7L4-no-unsplash-768x512.jpg 768w" sizes="(max-width: 1100px) 100vw, 1100px" /></div><p style="text-align: justify;">The <strong>Cuban drug Jusvinza</strong> is advancing to the<strong> second phase of clinical trials,</strong> demonstrating its effectiveness in <strong>relieving pain and inflammation in secondary joints in patients recovering from the chikungunya virus.</strong></p>
<p style="text-align: justify;">This was reported by <strong>Julio Baldomero, director of Clinical Research at the Center for Genetic Engineering and Biotechnology (CIGB).</strong></p>
<p style="text-align: justify;">According to the specialist, &#8220;the <strong>final data confirmed the hypothesis put forward by the researchers.&#8221;</strong> In this regard, Baldomero stated that they managed to <strong>resolve the “painful and inflammatory symptoms of the joints caused by this virus, which is transmitted by mosquitoes and has affected tropical regions of the world.”</strong></p>
<h3>What is Jusvinza?</h3>
<p style="text-align: justify;">The medication is essentially an <strong>innovative therapeutic product developed at the CIGB (Center for Genetic Engineering and Biotechnology).</strong> The active ingredient “is a<strong> peptide originally designed to treat rheumatoid arthritis” that was incorporated into the Cuban national protocol during the COVID-19 pandemic</strong> for use in “severely ill patients, helping to <strong>reduce mortality on the Caribbean island before the arrival of vaccines.”</strong></p>
<h3>Clinical trials with promising results</h3>
<figure id="attachment_120621" aria-describedby="caption-attachment-120621" style="width: 373px" class="wp-caption alignleft"><img decoding="async" class="wp-image-120621 " src="https://bitfinance.news/wp-content/uploads/2026/04/nathan-rimoux-AqVLU4cx8OI-unsplash-200x300.jpg" alt="(Reference image source: Nathan Rimoux on Unsplash)" width="373" height="560" srcset="https://bitfinance.news/wp-content/uploads/2026/04/nathan-rimoux-AqVLU4cx8OI-unsplash-200x300.jpg 200w, https://bitfinance.news/wp-content/uploads/2026/04/nathan-rimoux-AqVLU4cx8OI-unsplash-683x1024.jpg 683w, https://bitfinance.news/wp-content/uploads/2026/04/nathan-rimoux-AqVLU4cx8OI-unsplash-768x1152.jpg 768w, https://bitfinance.news/wp-content/uploads/2026/04/nathan-rimoux-AqVLU4cx8OI-unsplash-1024x1536.jpg 1024w, https://bitfinance.news/wp-content/uploads/2026/04/nathan-rimoux-AqVLU4cx8OI-unsplash.jpg 1100w" sizes="(max-width: 373px) 100vw, 373px" /><figcaption id="caption-attachment-120621" class="wp-caption-text">(Reference image source: Nathan Rimoux on Unsplash)</figcaption></figure>
<p style="text-align: justify;"><strong>In early December 2025, two clinical trials began</strong> to verify the therapeutic effect and safety of Jusvinza in these types of patients.</p>
<p style="text-align: justify;">“The <strong>first study</strong> was conducted at the <strong>Diez de Octubre Clinical Surgical Teaching Hospital in Havana and included 174 people in the post-acute stage</strong>; while the <strong>second</strong> was carried out at the <strong>Faustino Pérez Provincial Clinical Surgical Teaching Hospital in the western province of Matanzas, with 120 individuals in the chronic stage of the disease.”</strong></p>
<p style="text-align: justify;">The conclusions of both studies indicate that<strong> 70 % of the patients achieved the expected results.</strong> Specialists demonstrated the efficacy and safety of the product. Furthermore, it was found that <strong>“it is not only effective in relieving joint symptoms, but its effects are long-lasting, preventing patients from developing the chronic form of the disease.”</strong></p>
<p style="text-align: justify;">M.Pino</p>
<p><em>Source: <a href="https://spanish.xinhuanet.com/20260404/324906aa46b640be8c4e269bdd00eb2e/c.html" target="_blank" rel="noopener">xinhuanet</a></em></p>
<p>(Reference image source: Louis Reed on Unsplash)</p>
<p style="text-align: left;"><em><strong>Follow our news on Google!</strong></em><em> For current, interesting, and accurate information, </em><a href="https://www.google.com/search?q=site:bitfinance.news&amp;tbm=nws&amp;tbs=sbd:1" target="_blank" rel="noopener"><strong><em>click here</em></strong></a><em> to see all the content on <strong>Bitfinance.news</strong>. You can also find us on </em><a href="https://twitter.com/BitFinance_News" target="_blank" rel="noopener"><strong><em>X/Twitter</em></strong></a><em> and </em><a href="https://www.instagram.com/bitfinancenews/?hl=es" target="_blank" rel="noopener"><strong><em>Instagram</em></strong></a></p>
<p>La entrada <a rel="nofollow" href="https://bitfinance.news/en/cuba-tests-drug-that-relieves-painful-aftereffects-of-chikungunya-virus/">Cuba tests drug that relieves painful aftereffects of Chikungunya virus</a> apareció primero en <a rel="nofollow" href="https://bitfinance.news">Bitfinance</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
